Ellevest Inc. Has $577,000 Stock Holdings in Edwards Lifesciences Corporation $EW

Ellevest Inc. cut its stake in Edwards Lifesciences Corporation (NYSE:EW) by 12.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,372 shares of the medical research company’s stock after selling 1,029 shares during the quarter. Ellevest Inc.’s holdings in Edwards Lifesciences were worth $577,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the stock. Cassaday & Co Wealth Management LLC acquired a new position in shares of Edwards Lifesciences in the second quarter worth $202,000. NewSquare Capital LLC increased its stake in shares of Edwards Lifesciences by 57.8% in the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock worth $29,000 after acquiring an additional 134 shares during the last quarter. Prosperity Consulting Group LLC increased its stake in shares of Edwards Lifesciences by 3.2% in the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company’s stock worth $337,000 after acquiring an additional 132 shares during the last quarter. Machina Capital S.A.S. acquired a new position in shares of Edwards Lifesciences in the second quarter worth $3,888,000. Finally, Burney Co. acquired a new position in shares of Edwards Lifesciences in the second quarter worth $2,857,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Down 1.5%

EW stock opened at $82.86 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a 52-week low of $64.89 and a 52-week high of $87.09. The company has a 50-day moving average of $77.72 and a two-hundred day moving average of $77.18. The stock has a market capitalization of $48.65 billion, a price-to-earnings ratio of 11.92, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the company earned $0.67 earnings per share. The business’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of the company’s stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This represents a 4.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.29% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on EW. Wells Fargo & Company upped their price target on shares of Edwards Lifesciences from $84.00 to $88.00 and gave the stock an “overweight” rating in a research note on Thursday, August 7th. Oppenheimer downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Robert W. Baird set a $83.00 target price on shares of Edwards Lifesciences in a research report on Friday, October 31st. Canaccord Genuity Group reissued a “hold” rating and set a $84.00 target price (up from $81.00) on shares of Edwards Lifesciences in a research report on Monday. Finally, The Goldman Sachs Group set a $104.00 target price on shares of Edwards Lifesciences and gave the stock a “buy” rating in a research report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $91.39.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.